MDM2 and osteosarcoma: p53 wt, MDM2 amplified human osteosarcoma SJSA-1 cells, previously shown to be sensitive to RG7388 and extensively used in the pre-clinical evaluation of several classes of MDM2-p53 antagonists to date, were used as a positive control [6, 8, 14-17] (Table 1).